Skip to content

WHITEHEAD INSTITUTE FOR BIOMEDICAL RES

CAMBRIDGE, MA

OncologyGrant-only

What changed

NIH K99 · $0.1M · Spatially-resolved, integrated cell state and lineage tracing to define progenitor cell dynamics in early mouse development

Feb 2025New grantFeb 20, 2025Source filing (opens the source filing in a new tab)

Momentum

20no change

Momentum 20 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

9,393 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources